Interchangeable Exclusivity: Pfizer To Rival Boehringer On Humira Biosimilar After US FDA Decision

 
• By Dave Wallace

FDA decision ends Boehringer Ingelheim’s exclusivity for interchangeable biosimilar of Humira after just a few months. Pfizer reveals pricing and launch information for its Abrilada version of adalimumab.

Hourglass timer dissolving, end of time period concept
The FDA decision has ended Boehringer’s exclusivity period • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics